Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study.

Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study.

Item

http://www.wikidata.org/entity/Q43996920

Q43996920

about

Systemic antibiotics for treating diabetic foot infections Antibiotic therapy for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) in non surgical wounds Carbapenems Development of a Health-Related Quality of Life Questionnaire (HRQL) for patients with Extremity Soft Tissue Infections (ESTI)Ertapenem versus piperacillin/tazobactam for the treatment of complicated infections: a meta-analysis of randomized controlled trials Epileptogenic potential of carbapenem agents: mechanism of action, seizure rates, and clinical considerations.Pharmacokinetics of ertapenem in healthy young volunteers.Pharmacokinetics and tolerability of single-dose intravenous ertapenem in infants, children, and adolescents Clinical microdialysis in skin and soft tissues: an update.Pharmacokinetics of intramuscularly administered ertapenem Treatment of bacterial skin and skin structure infections.Ceftaroline in complicated skin and skin-structure infections.Meropenem in the treatment of complicated skin and soft tissue infections Comparison of ertapenem and ceftriaxone therapy for acute pyelonephritis and other complicated urinary tract infections in Korean adults: a randomized, double-blind, multicenter trial.Ertapenem: review of a new carbapenem.Role of linezolid in the treatment of complicated skin and soft tissue infections.Tigecycline in the treatment of complicated intra-abdominal and complicated skin and skin structure infections.Ertapenem: the new carbapenem 5 years after first FDA licensing for clinical practice.Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination.The evaluation and treatment of complicated skin and skin structure infections.Antimicrobial prophylaxis in colorectal surgery: focus on ertapenem.Pharmacokinetic evaluation of piperacillin-tazobactam.A systematic review of the effectiveness of interventions in the management of infection in the diabetic foot.Diagnostics and treatment of the diabetic foot.From ulcer to infection: an update on clinical practice and adjunctive treatments of diabetic foot ulcers.Interventions in the management of infection in the foot in diabetes: a systematic review.Clinical efficacy of piperacillin/tazobactam in the treatment of complicated skin and soft tissue infections.Microbiota is a primary cause of pathogenesis of chronic wounds.Incidence of neutropenia during treatment of bone-related infections with piperacillin-tazobactam.Efficacy of ertapenem in severe hidradenitis suppurativa: a pilot study in a cohort of 30 consecutive patients.Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial.General microbiology and in vitro susceptibility of anaerobes isolated from complicated skin and skin-structure infections in patients enrolled in a comparative trial of ertapenem versus piperacillin-tazobactam.In vitro activity of ertapenem against common clinical isolates in relation to human pharmacokinetics.Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections.Clinical and economic consequences of failure of initial antibiotic therapy for hospitalized patients with complicated skin and skin-structure infections.Ertapenem-associated seizures in a peritoneal dialysis patient.Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections.

P2860

Q24187313-EB56332A-1B90-4A04-A4C4-0A56AFCC25F2 Q24202424-6AEA3024-1ACE-43D8-BFEB-A9F29300E0B9 Q28286055-6BE04997-2B34-4FCB-B49B-1E24434CA013 Q33260093-854F3E2D-E6B5-44D2-A1CB-8DC116196999 Q33516983-7D06A025-1107-4A21-AAC7-5A484464E4F0 Q34026343-DBC12AE4-C094-4069-ADC6-97A146A0157E Q34141850-CF25A13D-4777-4400-AD05-987E3CCA2E06 Q34348830-BED5329B-05E6-4A51-80A7-10984113ACCD Q34752069-48E6861A-8D10-4AC1-9BCC-368F159BED6F Q34938460-C5F9E242-4338-4ED4-916D-9DB15CF38AF4 Q35183731-8713933A-10C0-4D91-98FA-3AC4E8DFEF3B Q35715381-91EAAB62-89F0-4B55-B08B-E0250ACE2FF7 Q35919254-5EDF09CC-2B77-4FA7-8730-8D4C5F47F573 Q35928948-AF1D6301-4313-405F-9204-FB364CFA08C1 Q36066200-4F0EFD4F-7538-4093-A78D-919F9075098F Q36505478-FE6435EA-0176-4D4B-8A95-8BDE8853E987 Q36663656-9FD37324-14DF-4C5D-B576-E8BDB84106B6 Q36719706-6DA83CAB-FA93-4A77-AD9D-CA8BB5DE2964 Q36839703-75BDDE03-BF00-4F5A-A35E-C5F8666618AF Q37111836-6EEB4758-81FB-4D3E-A212-B5A5BF545666 Q37412959-1F76136A-D0E0-4C8F-9BFA-8BE771A586C8 Q37773368-FE805CA7-A166-471B-883C-E0B6E3AA3A51 Q37978286-44177C39-9DD5-4047-8337-EFD8801AC68A Q37988404-9A66839B-45F1-404C-BC3D-B144DDB569A3 Q38035802-98805E1F-F509-447D-A5F0-732EF1800E70 Q38582118-4DB1292F-A3AD-4B11-874F-801063533AAA Q39382608-589392BC-7E78-481F-91B0-0A44419544B2 Q40524232-96454B77-0D0C-443D-956E-020E160F4B78 Q40546181-0CD07F98-4D57-425F-B662-2F6F55FE1BFD Q40911079-5911C0B0-FFF4-41AD-97EF-2BB5CBE35F50 Q42681448-8F2CF82F-2538-4881-A4F8-AC3035FC1A2B Q44098411-690FC074-996E-49A7-84A7-069EBFE05491 Q44236347-40280DD9-557D-47A8-84C2-5A8A0B27DDF1 Q44635712-7E006168-3877-4281-B6A0-A69E8B42FE32 Q44958309-E6D3B405-9137-4572-947E-855F189EA9D2 Q45219997-D50EA88F-ADAA-4785-BCA9-09EF8A949D82 Q46758156-79EFDFE7-EC61-4173-ACF9-FF5ECAE7C8A9

P2860

Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study.

Item

http://www.wikidata.org/entity/Q43996920

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh

2002年學術文章

@zh-hant

name

Ertapenem once daily versus pi ...... ouble-blind multicenter study.

@en

Ertapenem once daily versus pi ...... ouble-blind multicenter study.

@nl

type

Item

label

Ertapenem once daily versus pi ...... ouble-blind multicenter study.

@en

Ertapenem once daily versus pi ...... ouble-blind multicenter study.

@nl

prefLabel

Ertapenem once daily versus pi ...... ouble-blind multicenter study.

@en

Ertapenem once daily versus pi ...... ouble-blind multicenter study.

@nl

P1476

Ertapenem once daily versus pi ...... ouble-blind multicenter study.

@en

P2093

Andrea McAdams

http://www.w3.org/2001/XMLSchema#string

Christopher Lucasti

http://www.w3.org/2001/XMLSchema#string

Donald R Graham

http://www.w3.org/2001/XMLSchema#string

Gail L Woods

http://www.w3.org/2001/XMLSchema#string

Nora Quintero Perez

http://www.w3.org/2001/XMLSchema#string

Osvaldo Malafaia

http://www.w3.org/2001/XMLSchema#string

Paul Holtom

http://www.w3.org/2001/XMLSchema#string

Richard Gesser

http://www.w3.org/2001/XMLSchema#string

Ronald L Nichols

http://www.w3.org/2001/XMLSchema#string

T Paulette Ceesay

http://www.w3.org/2001/XMLSchema#string

P2860

Some Methods for Strengthening the Common χ 2 Tests

Optimal treatment of complicated skin and skin structure infections.

Comparative In vitro activities of ertapenem (MK-0826) against 1,001 anaerobes isolated from human intra-abdominal infections.

Clinafloxacin versus piperacillin-tazobactam in treatment of patients with severe skin and soft tissue infections.

In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers.

Foot infections in diabetic patients: the role of anaerobes.

Bacteriology of skin and soft-tissue infections: comparison of infections in intravenous drug users and individuals with no history of intravenous drug use.

Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infect

P304

1460-1468

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/340348

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2002-05-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11355393

http://www.w3.org/2001/XMLSchema#string

P698

12015692

http://www.w3.org/2001/XMLSchema#string

Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study.

about

P2860

P2860

Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698